4D Molecular Therapeutics Shares Rise After New Credit Facility

Dow Jones06-29 22:34

4D Molecular Therapeutics were 7% higher, at $12.40, after the company said it has entered into a strategic credit-facility agreement with Hercules Capital for up to $200 million.

The biotechnology company said that even without this facility, its cash, cash equivalents and marketable-securities position is expected to continue to fund its planned operations into the second half of 2028.

Under the terms of the agreement, 4D Molecular drew an initial $20 million at closing. An additional $30 million is available, at the company's option, through June 15, 2027, with an additional $100 million available upon its achievement of certain milestones, 4D Molecular said. The remaining $50 million available is subject to final lender approval, it said.

The company said its cash, cash equivalents and marketable securities were $458 million as of March 31.

4D Molecular also said Monday that it completed enrollment for its second Phase 3 clinical trial evaluating 4D-150 in patients with wet age-related macular degeneration. 4D-150 is a potential backbone therapy designed to provide multiyear sustained delivery of anti-VEGF biologics within the retina following a single intravitreal injection, the company said.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

June 29, 2026 10:34 ET (14:34 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2647702033?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-29 22:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2647702033","market":"other","top_or_hot":-1,"title":"4D Molecular Therapeutics Shares Rise After New Credit Facility","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/FDMT\">4D Molecular Therapeutics</a> were 7% higher, at $12.40, after the company said it has entered into a strategic credit-facility agreement with Hercules Capital for up to $200 million. \n</p>\n<p>\n  The biotechnology company said that even without this facility, its cash, cash equivalents and marketable-securities position is expected to continue to fund its planned operations into the second half of 2028. \n</p>\n<p>\n  Under the terms of the agreement, 4D Molecular drew an initial $20 million at closing. An additional $30 million is available, at the company's option, through June 15, 2027, with an additional $100 million available upon its achievement of certain milestones, 4D Molecular said. The remaining $50 million available is subject to final lender approval, it said. \n</p>\n<p>\n  The company said its cash, cash equivalents and marketable securities were $458 million as of March 31. \n</p>\n<p>\n  4D Molecular also said Monday that it completed enrollment for its second Phase 3 clinical trial evaluating 4D-150 in patients with wet age-related macular degeneration. 4D-150 is a potential backbone therapy designed to provide multiyear sustained delivery of anti-VEGF biologics within the retina following a single intravitreal injection, the company said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 29, 2026 10:34 ET (14:34 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>4D Molecular Therapeutics Shares Rise After New Credit Facility</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n4D Molecular Therapeutics Shares Rise After New Credit Facility\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-29 22:34</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/FDMT\">4D Molecular Therapeutics</a> were 7% higher, at $12.40, after the company said it has entered into a strategic credit-facility agreement with Hercules Capital for up to $200 million. \n</p>\n<p>\n  The biotechnology company said that even without this facility, its cash, cash equivalents and marketable-securities position is expected to continue to fund its planned operations into the second half of 2028. \n</p>\n<p>\n  Under the terms of the agreement, 4D Molecular drew an initial $20 million at closing. An additional $30 million is available, at the company's option, through June 15, 2027, with an additional $100 million available upon its achievement of certain milestones, 4D Molecular said. The remaining $50 million available is subject to final lender approval, it said. \n</p>\n<p>\n  The company said its cash, cash equivalents and marketable securities were $458 million as of March 31. \n</p>\n<p>\n  4D Molecular also said Monday that it completed enrollment for its second Phase 3 clinical trial evaluating 4D-150 in patients with wet age-related macular degeneration. 4D-150 is a potential backbone therapy designed to provide multiyear sustained delivery of anti-VEGF biologics within the retina following a single intravitreal injection, the company said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 29, 2026 10:34 ET (14:34 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2647702033","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2647702033","pubTimestamp":1782743640,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"4D Molecular Therapeutics were 7% higher, at $12.40, after the company said it has entered into a strategic credit-facility agreement with Hercules Capital for up to $200 million.The biotechnology company said that even without this facility, its cash, cash equivalents and marketable-securities position is expected to continue to fund its planned operations into the second half of 2028.Under the terms of the agreement, 4D Molecular drew an initial $20 million at closing. An additional $30 million is available, at the company's option, through June 15, 2027, with an additional $100 million available upon its achievement of certain milestones, 4D Molecular said. The remaining $50 million available is subject to final lender approval, it said.The company said its cash, cash equivalents and marketable securities were $458 million as of March 31.4D Molecular also said Monday that it completed enrollment for its second Phase 3 clinical trial evaluating 4D-150 in patients with wet age-related","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","FDMT":"4D Molecular Therapeutics","HTGC":"海格投资","BK4135":"资产管理与托管银行"},"translate_title":"4D Molecular Therapeutics股价在新信贷安排后上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HTGC":0.9,"FDMT":1.5},"content_text":"4D Molecular Therapeutics were 7% higher, at $12.40, after the company said it has entered into a strategic credit-facility agreement with Hercules Capital for up to $200 million. \n\n\n  The biotechnology company said that even without this facility, its cash, cash equivalents and marketable-securities position is expected to continue to fund its planned operations into the second half of 2028. \n\n\n  Under the terms of the agreement, 4D Molecular drew an initial $20 million at closing. An additional $30 million is available, at the company's option, through June 15, 2027, with an additional $100 million available upon its achievement of certain milestones, 4D Molecular said. The remaining $50 million available is subject to final lender approval, it said. \n\n\n  The company said its cash, cash equivalents and marketable securities were $458 million as of March 31. \n\n\n  4D Molecular also said Monday that it completed enrollment for its second Phase 3 clinical trial evaluating 4D-150 in patients with wet age-related macular degeneration. 4D-150 is a potential backbone therapy designed to provide multiyear sustained delivery of anti-VEGF biologics within the retina following a single intravitreal injection, the company said. \n\n\n \n\n\n  Write to Chris Wack at chris.wack@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 29, 2026 10:34 ET (14:34 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2647702033","isCrawlerRequest":true}